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Guillain-Barre Syndrome

Tyler Skelton RN, BSN, CCRN
Otterbein University, Westerville, Ohio

Introduction
Guillain-Barre Syndrome consists of a
group of neuropathic conditions
characterized by progressive weakness
and diminished or absent myotatic
reflexes. The estimated annual incidence
in the United States is 1.65 to 1.79 per
100,000 persons (Walling & Dickson,
2013). Understanding how this condition
progresses and the affects it has on a
patient will assistant in providing optimal
patient care as a future nurse anesthetist.
As stated by Turakhia, P., Barrick, B., and
Berman, J. (2013) “the anesthetic
implications for the various comorbidities
are varied and can be profound” (p. 1). An
individual who suffers from Guillain-Barre
is a patient who certainly requires critical
care management in order to avoid
complications associated with the disease.
Being aware of the pathophysiology, risk
factors, signs and symptoms, and
treatment involved in caring for GuillainBarre Syndrome can better prepare the
advanced practicing nurse for patients
suffering from this condition.

Signs & Symptoms
The first symptoms include varying
degrees of weakness or tingling
sensations in the legs, that can spread to
the upper body. This can progress to
almost complete paralysis. Common
symptoms are: Facial droop, diplopias,
dysarthria, dysphagia, ophthalmoplegia,
pupillary disturbances, dyspnea on
exertion, shortness of breath, difficulty
swallowing, slurred speech. Autonomic
Symptoms include: Tachycardia,
bradycardia, facial flushing, paroxysmal
hypertension, orthostatic hypotension,
diaphoresis, urinary retention. Required
criteria for the diagnosis include:
Progressive weakness of more than two
limbs, areflexia, progression for no more
than four weeks (Sebastian, 2012).
Supportive criteria include: Relatively
mild sensory signs, raised protein in the
cerebrospinal fluid (CSF), with a relatively
normal cell count, neurophysiological
evidence of conduction block, weakness is
frequently proximal and distal, unlike
dying back axonopathies, and respiratory
involvement occurs in about a quarter of
cases. The CSF protein may be normal in
the first week of the illness, but may then
rise to several g/dl. The CSF cell count
usually remains below 500 cells/litre.
Oligoclonal bands are sometimes found in
the CSF. Routine blood tests sometimes
reveal a raised sedimentation rate with
hyponatraemia from inappropriate
antidiuretic hormone release, and mild
impairment of liver function tests is not
uncommon (Winer, 2001).

Underlying Pathophysiology
Subtypes of GBS include AIDP, AMAN, acute motor and sensory axonal neuropathy
(AMSAN), acute sensory axonal neuropathy (ASAN), and Miller–Fisher syndrome.
Electrophysiology is an important clinical tool for distinguishing demyelinating and
axonal subtypes, because it may reveal demyelination, loss of motor axons only, loss of
sensory axons only, or mixed loss (Franssen & Straver, 2014). Proposed mechanism
involves an antecedent infection leading to an autoimmune response reacting with
peripheral nerve components. Most of the pathogens gains entry to the body through
mucosal or gut epithelium and induce antibody production against specific gangliosides
in myelin. Proposed mechanism involves an antecedent infection leading to an
autoimmune response reacting with peripheral nerve components. Most of the
pathogens gains entry to the body through mucosal or gut epithelium and induce
antibody production against specific gangliosides in myelin. The immune response
depends on bacterial factors, such as the specificity of lipo-oligosaccharide (LOS), and on
host factors, such as genetic polymorphism and immune status. The presence of
antibodies leads to activation of T cells and complements, leading to a cascade of
inflammation and demyelination. The demyelination decreases the velocity of nerve
conduction and slows the impulse transmission along the axons. The extent of nerve
damage varies, with more damage seen in the intensely myelinated peripheral nerves,
causing motor and sensory weakness (Sebastian, 2012).Based on human observational
studies and data obtained from EAN models, it is hypothesized that CCR2 monocytes
cross the brain nerve barrier (BNB) via interaction with Schwann-cell-secreted CCL2
expressed by the BNB endothelium. These monocytes differentiate into endoneurial
macrophages that migrate to CCL2-expressing Schwann cells to induce demyelination.
CCR1/CCR5 macrophages may migrate to axons expressing CCL5 to induce axonal
degeneration. CXCR3 T cells may migrate across the BNB via interactions with BNB
endothelium CXCL10 and directly contribute to nerve injury via cytokine secretion or
expression of pro-inflammatory chemokines that further attract hematogenous
monocytes and lymphocytes, enhancing the inflammatory process (Chiang & Ubogu,
2013).

Implications For
Nursing Care
According to Dubey et al. (2016) “early identification of GBS may lead to earlier initiation
of management, including immunomodulatory therapy, intensive care unit admission in
selected patients, and multidisciplinary team involvement. The initial clinical diagnosis
of GBS may be challenging. Lack of evaluation by a neurologist, neuropathic pain,
preserved reflexes, and an atypical pattern of weakness were all associated with a delay
in considering the diagnosis of GBS. The delay in diagnosis had a significant impact on
outcome, as assessed by the clinical status at the time of discharge and the discharge
disposition” (p. 386). It is of the utmost importance that nurses identify signs of a
potential case of GBS as soon as possible in order to promote an optimal outcome for
patients. The primary nursing management of a patient with GBS should be centered on
problems with the airway related to respiratory muscle weakness or paralysis,
decreased cough reflex, and immobilization. Due to the progressive muscle weakness,
nurses should plan interventions that focus on preventing complications related to
immobility, such as ensuring skin integrity. (Moore & Shepard, 2014).

Significance of Pathophysiology

Guillain Barre Syndrome can occur in any patient. It typically involves initial insult from injury or is preceded by an infection, leading
to demyelination of the nerves. Understanding risk factors and how GBS presents itself can aid in early diagnosis. It is detrimental that
those caring for patients be educated on the signs and symptoms, and be prepared to intervene as necessary to reduce the risk of
complications. Interdisciplinary collaboration and careful management can help reduce the length of recovery and promote better
outcomes for affected individuals.
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Treatment

It is of utmost importance to understand the pathophysiology of Guillain-Barre
Syndrome. Having an understanding of how it progresses and manifests itself can lead
to quick diagnosis and intervention. Prevention of life-threatening complications
remains the cornerstone of supportive care. Progressive demyelination of the phrenic
nerve, innervating the diaphragm, may lead to acute respiratory muscle paralysis. Early
detection of respiratory failure and anticipation of mechanical ventilation are crucial to
avoid emergency intubation and cardiopulmonary arrest. Life-threatening episodes of
hemodynamic instability related to autonomic dysfunction may occur in GBS patients.
They should be admitted to the hospital for close monitoring of respiratory status,
hemodynamic instability, and autonomic dysfunction (Sebastian, 2012).

Conclusion

Based on strong research evidence in adults, IVIG and plasma exchange hasten recovery
from GBS in patients with impaired ability to ambulate (Rosen, 2012). Common
treatment modalities include corticosteroids, intravenous immunoglobulin (IVIg),
therapeutic plasma exchange (TPE), cerebral spinal fluid (CSF) filtration, and
immunoadsorption. Treatment with intravenous immunoglobulin and plasma exchange
reduces the time for recovery to occur, although some remain disabled (McNair, 2013).
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